🚀 VC round data is live in beta, check it out!
China SXT Pharmaceuticals Valuation Multiples
Discover revenue and EBITDA valuation multiples for China SXT Pharmaceuticals and similar public comparables like Gabather, Nextgen Biomed, ExpreS2ion Biotech, Biosenic and more.
China SXT Pharmaceuticals Overview
About China SXT Pharmaceuticals
China SXT Pharmaceuticals Inc is a pharmaceutical company that is focused on the research, development, manufacture, marketing, and sales of Traditional Chinese Medicine Pieces (TCMP), particularly, TCMP (Directed-oral TCMP, and After-soaking TCMP) which is a sort of Traditional Chinese Medicine (TCM) that has been processed to be ready for use without decoction. Geographically, the firm generates its revenue from the People's Republic of China.
Founded
2017
HQ
Employees
75
Website
Sectors
Financials (FY)
Market Cap
$2M
China SXT Pharmaceuticals Financials
China SXT Pharmaceuticals reported last fiscal year revenue of $2M and negative EBITDA of ($3M).
In the same fiscal year, China SXT Pharmaceuticals generated $367K in gross profit, ($3M) in EBITDA losses, and had net loss of ($3M).
China SXT Pharmaceuticals P&L
In the most recent fiscal year, China SXT Pharmaceuticals reported revenue of $2M and EBITDA of ($3M).
China SXT Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $2M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $367K | XXX | XXX | XXX |
| Gross Margin | — | XXX | 21% | XXX | XXX | XXX |
| EBITDA | — | XXX | ($3M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (148%) | XXX | XXX | XXX |
| EBIT Margin | — | XXX | (154%) | XXX | XXX | XXX |
| Net Profit | — | XXX | ($3M) | XXX | XXX | XXX |
| Net Margin | — | XXX | (190%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
China SXT Pharmaceuticals Stock Performance
China SXT Pharmaceuticals has current market cap of $2M.
Market Cap Evolution
China SXT Pharmaceuticals' stock price is $2.32.
| Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|
| $2M | 0.0% | XXX | XXX | XXX | $-3.87 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialChina SXT Pharmaceuticals Valuation Multiples
China SXT Pharmaceuticals trades at (10.3x) EV/Revenue multiple, and 7.0x EV/EBITDA.
China SXT Pharmaceuticals Financial Valuation Multiples
As of April 12, 2026, China SXT Pharmaceuticals has market cap of $2M.
Equity research analysts estimate China SXT Pharmaceuticals' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
China SXT Pharmaceuticals has a P/E ratio of (0.6x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2M | XXX | $2M | XXX | XXX | XXX |
| EV (current) | ($18M) | XXX | ($18M) | XXX | XXX | XXX |
| EV/Revenue | — | XXX | (10.3x) | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 7.0x | XXX | XXX | XXX |
| EV/EBIT | — | XXX | 6.7x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | (48.9x) | XXX | XXX | XXX |
| P/E | — | XXX | (0.6x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | 7.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified China SXT Pharmaceuticals Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
China SXT Pharmaceuticals Margins & Growth Rates
China SXT Pharmaceuticals' revenue in the last fiscal year declined by (3%).
China SXT Pharmaceuticals' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.0M for the same period.
China SXT Pharmaceuticals Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | (3%) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (148%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 2% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 17% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 158% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 175% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
China SXT Pharmaceuticals Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Gabather | XXX | XXX | XXX | XXX | XXX | XXX |
| Nextgen Biomed | XXX | XXX | XXX | XXX | XXX | XXX |
| ExpreS2ion Biotech | XXX | XXX | XXX | XXX | XXX | XXX |
| Biosenic | XXX | XXX | XXX | XXX | XXX | XXX |
| Biophytis | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
China SXT Pharmaceuticals M&A Activity
China SXT Pharmaceuticals acquired XXX companies to date.
Last acquisition by China SXT Pharmaceuticals was on XXXXXXXX, XXXXX. China SXT Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by China SXT Pharmaceuticals
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialChina SXT Pharmaceuticals Investment Activity
China SXT Pharmaceuticals invested in XXX companies to date.
China SXT Pharmaceuticals made its latest investment on XXXXXXXX, XXXXX. China SXT Pharmaceuticals invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by China SXT Pharmaceuticals
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout China SXT Pharmaceuticals
| When was China SXT Pharmaceuticals founded? | China SXT Pharmaceuticals was founded in 2017. |
| Where is China SXT Pharmaceuticals headquartered? | China SXT Pharmaceuticals is headquartered in China. |
| How many employees does China SXT Pharmaceuticals have? | As of today, China SXT Pharmaceuticals has over 75 employees. |
| Who is the CEO of China SXT Pharmaceuticals? | China SXT Pharmaceuticals' CEO is Feng Zhou. |
| Is China SXT Pharmaceuticals publicly listed? | Yes, China SXT Pharmaceuticals is a public company listed on Nasdaq. |
| What is the stock symbol of China SXT Pharmaceuticals? | China SXT Pharmaceuticals trades under SXTC ticker. |
| When did China SXT Pharmaceuticals go public? | China SXT Pharmaceuticals went public in 2019. |
| Who are competitors of China SXT Pharmaceuticals? | China SXT Pharmaceuticals main competitors are Gabather, Nextgen Biomed, ExpreS2ion Biotech, Biosenic. |
| What is the current market cap of China SXT Pharmaceuticals? | China SXT Pharmaceuticals' current market cap is $2M. |
| What is the current revenue of China SXT Pharmaceuticals? | China SXT Pharmaceuticals' last fiscal year revenue is $2M. |
| What is the current EV/Revenue multiple of China SXT Pharmaceuticals? | Current revenue multiple of China SXT Pharmaceuticals is (10.3x). |
| Is China SXT Pharmaceuticals profitable? | No, China SXT Pharmaceuticals is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.